JP2016539122A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539122A5 JP2016539122A5 JP2016533187A JP2016533187A JP2016539122A5 JP 2016539122 A5 JP2016539122 A5 JP 2016539122A5 JP 2016533187 A JP2016533187 A JP 2016533187A JP 2016533187 A JP2016533187 A JP 2016533187A JP 2016539122 A5 JP2016539122 A5 JP 2016539122A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- treatment
- administered
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201314086696A | 2013-11-21 | 2013-11-21 | |
| CA2834000 | 2013-11-21 | ||
| EP13193953.0 | 2013-11-21 | ||
| EP13193953.0A EP2875827A1 (en) | 2013-11-21 | 2013-11-21 | Preparations and methods for treating a GD2 positive cancer |
| US14/086,696 | 2013-11-21 | ||
| CA2834000A CA2834000A1 (en) | 2013-11-21 | 2013-11-21 | Method for treating a gd2 positive cancer |
| US14/182,776 US10294305B2 (en) | 2012-06-18 | 2014-02-18 | Method for treating a GD2 positive cancer |
| US14/182,776 | 2014-02-18 | ||
| PCT/EP2014/075315 WO2015075194A1 (en) | 2013-11-21 | 2014-11-21 | Preparations and methods for treating a gd2 positive cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019142173A Division JP7139293B2 (ja) | 2013-11-21 | 2019-08-01 | Ｇｄ２陽性がんを処置するための製剤および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016539122A JP2016539122A (ja) | 2016-12-15 |
| JP2016539122A5 true JP2016539122A5 (https=) | 2017-08-31 |
| JP6693873B2 JP6693873B2 (ja) | 2020-05-13 |
Family
ID=53179006
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016533187A Active JP6693873B2 (ja) | 2013-11-21 | 2014-11-21 | Ｇｄ２陽性がんを処置するための製剤および方法 |
| JP2019142173A Active JP7139293B2 (ja) | 2013-11-21 | 2019-08-01 | Ｇｄ２陽性がんを処置するための製剤および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019142173A Active JP7139293B2 (ja) | 2013-11-21 | 2019-08-01 | Ｇｄ２陽性がんを処置するための製剤および方法 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US10995147B2 (https=) |
| EP (2) | EP3071220B1 (https=) |
| JP (2) | JP6693873B2 (https=) |
| AU (2) | AU2014351796B2 (https=) |
| CA (1) | CA2930285A1 (https=) |
| CY (1) | CY1122508T1 (https=) |
| DK (1) | DK3071220T3 (https=) |
| EA (1) | EA201691055A1 (https=) |
| ES (1) | ES2768649T3 (https=) |
| HR (1) | HRP20200128T1 (https=) |
| HU (1) | HUE047920T2 (https=) |
| LT (1) | LT3071220T (https=) |
| NZ (1) | NZ720273A (https=) |
| PL (1) | PL3071220T3 (https=) |
| PT (1) | PT3071220T (https=) |
| RS (1) | RS59817B1 (https=) |
| SI (1) | SI3071220T1 (https=) |
| SM (1) | SMT202000027T1 (https=) |
| WO (1) | WO2015075194A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013189516A1 (en) | 2012-06-18 | 2013-12-27 | Apeiron Biologics Ag | Method for treating a gd2 positive cancer |
| US9840566B2 (en) | 2013-11-21 | 2017-12-12 | Apeiron Biologics Ag | Preparations and methods for treating a GD2 positive cancer |
| ES2768649T3 (es) * | 2013-11-21 | 2020-06-23 | Apeiron Biologics Ag | Preparaciones para tratar un cáncer positivo para GD2 |
| RU2663104C1 (ru) * | 2017-07-13 | 2018-08-01 | Общество с ограниченной ответственностью "Реал Таргет" | Получение пегилированных фрагментов gd2-специфичных антител, индуцирующих прямую клеточную гибель gd2-позитивных опухолевых клеток, и их применение в терапии gd2-позитивных опухолей |
| EP3684818A2 (en) | 2017-09-21 | 2020-07-29 | UMC Utrecht Holding B.V. | Anti-gd2 antibody for the treatment of neuroblastoma |
| MX2023000384A (es) * | 2020-07-06 | 2023-06-16 | Eusa Pharma Uk Ltd | Metodo para tratar un cancer positivo para gd2. |
| WO2026053122A1 (en) * | 2024-09-04 | 2026-03-12 | Dana-Farber Cancer Institute, Inc. | Methods of treating retinoid responsive cancers |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4863713A (en) | 1986-06-23 | 1989-09-05 | The Board Of Trustees Of Leland Stanford Jr. Univ. | Method and system for administering therapeutic and diagnostic agents |
| KR20030074693A (ko) | 2000-12-28 | 2003-09-19 | 알투스 바이올로직스 인코포레이티드 | 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법 |
| US7455833B2 (en) | 2002-07-15 | 2008-11-25 | Board Of Regents, The University Of Texas System | Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids |
| WO2004055056A1 (en) | 2002-12-17 | 2004-07-01 | Merck Patent Gmbh | Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2 |
| AU2005206277B2 (en) | 2004-01-22 | 2011-06-23 | Merck Patent Gmbh | Anti-cancer antibodies with reduced complement fixation |
| US7807409B2 (en) | 2005-10-21 | 2010-10-05 | Roche Palo Alto Llc | Method for the recombinant expression of a polypeptide |
| EP1916257A1 (en) * | 2006-10-27 | 2008-04-30 | Charite-Universitätsmedizin Berlin | GD2 peptide mimotopes for anticancer vaccination |
| CN102164962B (zh) | 2008-06-30 | 2014-05-28 | 诺福泰克公司 | 抗gd2抗体和方法及其相关应用 |
| EP3323830B1 (en) | 2010-06-19 | 2023-08-23 | Memorial Sloan-Kettering Cancer Center | Anti-gd2 antibodies |
| JP5623999B2 (ja) | 2010-08-31 | 2014-11-12 | パナソニック株式会社 | 電子装置 |
| SG11201401422VA (en) | 2011-10-27 | 2014-09-26 | Genmab As | Production of heterodimeric proteins |
| EP4218811A1 (en) | 2012-06-18 | 2023-08-02 | Apeiron Biologics AG | Method for treating a gd2 positive cancer |
| WO2013189516A1 (en) | 2012-06-18 | 2013-12-27 | Apeiron Biologics Ag | Method for treating a gd2 positive cancer |
| ES2768649T3 (es) | 2013-11-21 | 2020-06-23 | Apeiron Biologics Ag | Preparaciones para tratar un cáncer positivo para GD2 |
| US9840566B2 (en) | 2013-11-21 | 2017-12-12 | Apeiron Biologics Ag | Preparations and methods for treating a GD2 positive cancer |
-
2014
- 2014-11-21 ES ES14802642T patent/ES2768649T3/es active Active
- 2014-11-21 SI SI201431460T patent/SI3071220T1/sl unknown
- 2014-11-21 EP EP14802642.0A patent/EP3071220B1/en active Active
- 2014-11-21 HR HRP20200128TT patent/HRP20200128T1/hr unknown
- 2014-11-21 CA CA2930285A patent/CA2930285A1/en active Pending
- 2014-11-21 DK DK14802642.0T patent/DK3071220T3/da active
- 2014-11-21 LT LTEP14802642.0T patent/LT3071220T/lt unknown
- 2014-11-21 NZ NZ720273A patent/NZ720273A/en unknown
- 2014-11-21 WO PCT/EP2014/075315 patent/WO2015075194A1/en not_active Ceased
- 2014-11-21 PT PT148026420T patent/PT3071220T/pt unknown
- 2014-11-21 SM SM20200027T patent/SMT202000027T1/it unknown
- 2014-11-21 JP JP2016533187A patent/JP6693873B2/ja active Active
- 2014-11-21 EP EP19203951.9A patent/EP3620173A1/en not_active Withdrawn
- 2014-11-21 HU HUE14802642A patent/HUE047920T2/hu unknown
- 2014-11-21 PL PL14802642T patent/PL3071220T3/pl unknown
- 2014-11-21 AU AU2014351796A patent/AU2014351796B2/en active Active
- 2014-11-21 RS RS20200053A patent/RS59817B1/sr unknown
- 2014-11-21 EA EA201691055A patent/EA201691055A1/ru unknown
-
2019
- 2019-08-01 JP JP2019142173A patent/JP7139293B2/ja active Active
-
2020
- 2020-01-21 CY CY20201100048T patent/CY1122508T1/el unknown
- 2020-05-22 AU AU2020203346A patent/AU2020203346A1/en not_active Abandoned
- 2020-07-06 US US16/920,880 patent/US10995147B2/en active Active
-
2021
- 2021-03-03 US US17/190,792 patent/US11492412B2/en active Active
-
2023
- 2023-03-06 US US18/178,778 patent/US20240158530A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016539122A5 (https=) | ||
| JP2015521607A5 (https=) | ||
| ZA202107358B (en) | Method for treating alzheimer's disease | |
| Perez et al. | Update on the use of immunoglobulin in human disease: a review of evidence | |
| MX2021002321A (es) | Nuevos metodos. | |
| MX2018015393A (es) | Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo. | |
| EA033400B1 (ru) | Антитело против cd3 и его применение | |
| PH12015501531A1 (en) | Crenolanib for treating flt3 mutated proliferative disorders | |
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| MX2020010119A (es) | Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo. | |
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| MX2025001920A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina | |
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| ZA202201946B (en) | Anti-bcma antibody, antigen-binding fragment thereof and medical use thereof | |
| MX2021004120A (es) | Regimen de dosificacion para antagonistas de tfpi. | |
| MX2017002841A (es) | Metodos para tratar enfermedades autoinmunes con el uso de un anticuerpo de dominio dirigido contra cd40l. | |
| PH12017500617A1 (en) | Dosage regimen for pegylated interferon | |
| JP2018522881A5 (https=) | ||
| Slade et al. | Changing practice: no need to stop ACE inhibition for venom immunotherapy | |
| FI3298042T3 (fi) | B-solujen vähentyminen diagnostisena merkkinä | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| JP2017530142A5 (https=) | ||
| MX2021003668A (es) | Composición de ketamina para su uso en un método de tratamiento de la depresión por administración pulmonar. | |
| EA202090416A1 (ru) | Способы лечения симптомов гастропареза с использованием велусетрага | |
| HK1236975A1 (en) | Method for treating alzheimer's disease |